Products
Platform
Research
Market
Learn
Partner
Support
IPO

L

Lupin Share Price

2105.3
+2.50 (0.12%)
LUPIN • 02 Jan, 2026 | 03:29 PM
Buywith MTF at 4.93x leverage

1Y Annualised Return

-12.24%

3Y Annualised Return

41.82%

5Y Annualised Return

15.43%

10Y Annualised Return

1.66%

The current prices are delayed, login or Open Demat Account for live prices.

Lupin Stock Performance

1W Return-0.34
1Y Return-12.14
Today's Low2095.5
Prev. Close2,102.80
Mkt Cap (Cr.)96,169.85
1M Return1.09
3Y Return187.28
52-Week High2402.9
Open2,103.00
PE Ratio18.03
6M Return6.95
Today's High2122.1
52-Week Low1795.2
Face Value2

Lupin Company background

Founded in: 1983
Managing director: Nilesh Deshbandhu Gupta.

Lupin Limited is a top pharmaceutical company in India, globally recognized for its research and innovation orientation. It was established in 1968 by Dr. Desh Bandhu Gupta with a humble vision, which was to provide medicines at affordable prices to all and fulfill medical requirements that were not fulfilled. Lupin has become a worldwide giant over the years, manufacturing a broad array of drugs such as branded and generic medicines, biotechnology items, and essential ingredients used in the production of other drugs.

A Global Pharmaceutical Powerhouse

Lupin’s journey from a domestic-focused company to an internationally recognized pharmaceutical leader shows its relentless pursuit of excellence. The company operates in over 100 countries across North America, Europe, Asia-Pacific, and Africa. It’s headquartered in Mumbai, India. It has quite a strong presence in developed markets such as the United States, where it is among the top five generic pharmaceutical companies by prescriptions. Additionally, Lupin is a prominent player in emerging markets, catering to the healthcare needs of millions with high-quality and affordable medications.

Innovation has been one of the most important cornerstones of Lupin's growth strategy. The company has invested significantly in research and development (R&D), establishing many state-of-the-art facilities across the world. These R&D centers focus greatly on creating complex generics, biosimilars, and specialty products, demonstrating Lupin’s commitment to advancing healthcare solutions. Lupin’s prowess in R&D has led to a robust pipeline of products that address quite a few therapeutic areas, including cardiovascular diseases, respiratory ailments, central nervous system disorders, diabetes, and oncology.

Therapeutic Expertise

Lupin's wide-ranging product portfolio covers a fairly substantial number of therapeutic areas. It holds a leadership position in anti-tuberculosis treatments, reflecting its dedication to combating global health challenges. Also, the company has made great strides in therapies for cardiovascular health, diabetes management, respiratory conditions, and women’s health. Lupin has managed to solidify its reputation as a trusted partner in the pharmaceutical industry by aligning its products with the needs of not only patients but also healthcare providers.

Manufacturing Excellence

Lupin's production facilities are among the strongest forces behind its success. The organization has numerous top-notch production facilities approved by top regulatory bodies like the US FDA, UK MHRA, and WHO. All these facilities have a fair number of state-of-the-art technologies to produce medicines of high quality. Lupin's focus on upholding high-quality standards reflects its commitment towards providing safe and effective pharmaceutical drugs to markets all around the world.

Strategic Acquisitions and Partnerships

Lupin has strategically expanded its reach and capabilities through acquisitions and partnerships. The acquisition of Gavis Pharmaceuticals and Novel Laboratories in the United States marked a great milestone in strengthening Lupin’s position in the world’s largest pharmaceutical market. The company’s partnerships with global pharmaceutical leaders have also enabled it to enhance its product offerings and cater to unmet medical needs.

Commitment to Sustainability

Other than its business activities, Lupin is greatly dedicated to corporate social responsibility and sustainable practices. Also, the firm is actively engaged in minimizing its environmental impact through green initiatives and optimal use of resources. Lupin's philanthropic organization, the Lupin Human Welfare and Research Foundation (LHWRF), has played a great role in empowering underprivileged society by focusing on healthcare, education, and skill development initiatives.

Financial Performance and Market Presence

Lupin has consistently delivered robust financial performance, driven by its diversified product portfolio, geographic expansion, and operational efficiency. The company’s ability to adapt to evolving market dynamics has also allowed it to maintain quite a competitive edge in the global pharmaceutical space. Investors often monitor Lupin share price as a barometer of the company’s market strength as well as its future prospects.

Brief Overview

While Lupin continues on its growth and innovation journey, it is always extremely committed to tackling new healthcare issues that emerge. The company is actively exploring new therapeutic areas, leveraging digital technologies, and enhancing its R&D capabilities to deliver breakthrough solutions. By staying true to its founding principles and embracing a forward-looking approach, Lupin aims to create a lasting impact on global healthcare.

Lupin Limited’s story is one of resilience, innovation, and commitment to improving lives. From its humble beginnings to becoming a global pharmaceutical powerhouse, Lupin has consistently demonstrated its ability to adapt and thrive in a dynamic industry. With its unwavering focus on quality, sustainability, and patient-centric solutions, Lupin is well-positioned to lead the future of healthcare innovation.

Lupin Financial Highlights


For the full year FY2025–2026, revenue reached ₹22903.72 crore and profit touched at ₹3306.26 crore. As of Sep '25, Lupin’s market capitalisation stood at ₹96,169.85 crores. Shareholding as of Sep '25 shows promoters holding 46.9%, with FIIs at 20.5%, DIIs at 26.6%, and public at 6.1%.

Lupin Share Price Today


As of 2 Jan 2026, Lupin share price is ₹2105.3. The stock opened at ₹2103 and had closed at ₹2102.8 the previous day. During today’s trading session, Lupin share price moved between ₹2,095.50 and ₹2,122.10, with an average price for the day of ₹2108.80. Over the last 52 weeks, the stock has recorded a low of ₹1,795.20 and a high of ₹2,402.90. In terms of performance, Lupin share price has increased by 7.4% over the past six months and has declined by 12.24% over the last year.
Read More
Lupin SIP Return Calculator
5,000
Over the past
Total Investment of ₹0
Monthly SIP of 5,000 would have become 0 in 5 years with a gain of 0 (+0.00%)
View details of Market Depth

Lupin Fundamental

Market Cap (in crs)

96,169.85

Face Value

2

Turnover (in lacs)

5,324.47

Key Metrics

Qtr Change %
6.3
Dividend yield 1yr %
Below industry Median
0.6

Lupin Key Financials

View more
Loading chart...
Lupin Quarterly Revenue
Lupin Yearly Revenue
Lupin Quarterly Net Profit/Loss
Lupin Yearly Net Profit/Loss

Lupin Result Highlights

  • Lupin Ltd reported a 12.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 24.9%.

  • Its expenses for the quarter were up by 4.0% QoQ and 10.1% YoY.

  • The net profit increased 21.6% QoQ and increased 72.8% YoY.

  • The earnings per share (EPS) of Lupin Ltd stood at 32.28 during Q2 FY 2025-26.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Lupin Shareholding Pattern

Promoter
46.9%
Foreign Institutions
20.5%
Mutual Funds
20.6%
Domestic Institutions
26.6%
Public
6.1%

Lupin Technical Analysis

Moving Averages Analysis
2105.3
Current Price
Bullish Moving Averages
15
Bearish Moving Averages
1
Day EMA5
2,102.30
Day EMA10
2,101.80
Day EMA12
2,100.90
Day EMA20
2,093.70
Day EMA26
2,086.50
Day EMA50
2,058.30
Day EMA100
2,026.60
Day EMA200
2,003.20
Delivery & Volume
Loading chart...

Day

56.20%

Week

58.80%

Month

65.20%

Delivery & Volume

2,107.63
Pivot
Resistance
First Resistance
2,119.77
Second Resistance
2,134.23
Third Resistance
2,146.37
Support
First Support
2,093.17
Second support
2,081.03
Third Support
2,066.57
Relative Strength Index
56.06
Money Flow Index
43.31
MACD
14.42
MACD Signal
18.57
Average True Range
31.94
Average Directional Index
18.16
Rate of Change (21)
1.21
Rate of Change (125)
7.70
Compare

Lupin Latest News

30 DEC 2025 | Tuesday
29 DEC 2025 | Monday
29 DEC 2025 | Monday

Please be aware that Lupin stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account